MSTN and oculopharyngeal muscular dystrophy: To monitor the effects of inhibiting myostatin in a mouse model of OPMD, where the disease is already established, 8–10 male A17 and FvB mice at 42 weeks of age were weighed and the anti-myostatin antibody RK35 (10 mg/kg IP) or an equivalent volume of saline was administered weekly for 10 weeks (Figure 1A).